(Q52026842)

20 April 2018

title

Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects. (English)

1 reference

20 April 2018

author name string

Larsen CS

1

1 reference

20 April 2018

Ostergård L

2

1 reference

20 April 2018

Møller BK

3

1 reference

20 April 2018

Buhl MR

4

1 reference

20 April 2018

publication date

1 January 2000

1 reference

20 April 2018

published in

Infectious Diseases

1 reference

20 April 2018

volume

32

1 reference

20 April 2018

issue

2

1 reference

20 April 2018

page(s)

153-160

1 reference

20 April 2018

The human immunodeficiency virus: infectivity and mechanisms of pathogenesis

cites work

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

A TH1-->TH2 switch is a critical step in the etiology of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Antiretroviral drugs for AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Interleukin 2: the molecule and its function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Cellular environments and apoptosis: tissue microenvironments control activated T-cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

How immune-based interventions can change HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655400750045259

10.1080/003655400750045259

21 January 2018

Identifiers

DOI

1 reference

20 April 2018

1 reference

20 April 2018